News
-
GLP-1 receptor agonists for managing OSA: Practical insights from an endocrinologist-sleep specialist
Brian Wojeck, MD, MPH, outlines the clinical considerations sleep medicine specialists will increasingly need to know to treat patients with obesity-related sleep apnea.
-
RSV vaccination boosts antibody titers in individuals with compromised immune systems
Rachana Krishna, MBBS, MSCR, said that while a recent study may not provide the ideal efficacy outcome data, the results are still helpful in counseling this patient population.
-
Novel obesity medications open door to new era in treatment of OSA
In December 2024, the FDA approved tirzepatide, a dual GIP and GLP-1 receptor agonist previously approved for type 2 diabetes and obesity, as the first prescription medication for adults with moderate to severe OSA and obesity.
-
COVID-19 immune patterns offer hope for future IPF treatment
Jose D. Herazo-Maya, MD, and colleagues are investigating a mechanism of T-cell suppression that may contribute to the development of a treatment for pulmonary fibrosis.
-
Understanding high-risk factors like PM2.5 in lung cancer
Renelle Myers, MD, FRCPC, discusses factors beyond tobacco use that clinicians should consider when screening for lung cancer, such as pollution exposure.
-
Study demonstrates viability of biologics for severe asthma, COPD exacerbations in eosinophilic inflammation
While larger studies are needed, Dharani K. Narendra, MD, FCCP, said the findings from the ABRA trial could be a game changer and reduce the need for glucocorticoids for some patients.
-
Growing evidence links perinatal exposures and childhood asthma risk
Research by Christian Rosas-Salazar, MD, MPH, is improving understanding of mechanisms at play from such exposures as antibiotics, RSV, tobacco smoke, and more.
-
Athletes require special considerations for everything from respiratory viruses to cardiovascular concerns
Eli Friedman, MD, said that when treating athletes, clinicians must consider their unique needs and how their high activity levels may impact their health care journey.
-
Updates in ninth edition of TNM classification criteria allow for more precise lung cancer staging
Hisao Asamura, MD, said the changes are critical to clinical decision-making in the evolving thoracic oncology treatment landscape.
-
Exploring the evolving landscape in combination therapies for EGFR-mutated advanced NSCLC
Susan Scott, MD, discussed the findings from the MARIPOSA and FLAURA2 trials and the next steps to identify who may benefit from which regimen.
